ProShares UltraShort NASDAQ Biotechnology
3 hedge funds and large institutions have $50.2K invested in ProShares UltraShort NASDAQ Biotechnology in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
Holders
3
Holders Change
-4
Holders Change %
-57.14%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
UBS Group
Zurich,
Switzerland
|
$46.4K |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $46.4K | 2,364 | +2,363 | +236,300% |
|
2
Morgan Stanley
New York
| $2.1K | 107 | – | – |
|
3
Citigroup
New York
| $1.67K | 85 | – | – |
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | – | -58,865 | Closed |
|
5
Citadel Advisors
Miami,
Florida
| – | – | -25,806 | Closed |
|
6
IMC Chicago
Chicago,
Illinois
| – | – | -23,335 | Closed |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | – | -8,123 | Closed |
|
|
CFGS
8
Concourse Financial Group Securities
Birmingham,
Alabama
| – | – | – | – |
|